Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2012 16:35 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2012

PHILADELPHIA, May 7, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the three months ended March 31, 2012. The net loss for the period (including...
April 30, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Test of Ampligen(R) With FluMist

PHILADELPHIA, April 30, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that Ampligen®, an experimental immunotherapeutic, has been...
March 26, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)

Incidence of NABs Induced Against Natural IFNs, Such as Alferon N Injection®, Was Very Low (<0.2%) and Significantly Less Than for Recombinant IFNs PHILADELPHIA, March 26, 2012 (GLOBE...
March 20, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Host 2011 Year End Conference Call on Thursday, March 22, 2012

PHILADELPHIA, March 20, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, March 22, 2012 at 10:00 a.m....
March 19, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Publishes Data on the Bioactivity of Ampligen(R) in Chronic Fatigue Syndrome ("CFS")

PHILADELPHIA, March 19, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced the publication of a peer-reviewed article providing the results...
March 14, 2012 15:02 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Fiscal 2011 Year Results

PHILADELPHIA, March 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the fiscal year ended December 31, 2011. The net loss for 2011's twelve month...
January 26, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Gains Regulatory Approval in Latin America

PHILADELPHIA, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that ANMAT (Administracion Nacional de Medicamentos,...
January 17, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO

PHILADELPHIA, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today the granting of two new United States Patents for the use of...
January 11, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

FDA Grants Hemispherx Biopharma Extension in Its Pending New Drug Application (NDA) for the Treatment of Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Jan. 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration ("FDA") granted an...
December 08, 2011 16:15 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma's 2011 Stockholder Annual Meeting Final Results

PHILADELPHIA, Dec. 8, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") has concluded its 2011 Stockholder Annual Meeting with the passage of Proposal No. 4 to...